PTC Therapeutics (PTCT) has released an update to notify the public and investors about a regulation fd disclosure.
PTC Therapeutics, Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has delivered a negative opinion on the renewal of the conditional marketing authorization for Translarna™ (ataluren) after a re-examination. This information, including related exhibits, is not considered “filed” under the Securities Exchange Act and is not to be integrated into any filings unless specifically referenced. Website addresses provided are for informational purposes and are not intended as active links.
For further insights into PTCT stock, check out TipRanks’ Stock Analysis page.
